Photo Credit: DC Studio
The Following is a Summary of “Factors Associated with Serum Concentrations of Vancomycin Crystalline Degradation Product (CDP-1) Pavors with Chronic Kidney Disease,” Published in the April 2025 Issue of BMC Nephrology by Xu et al.
RESEARCHERS DRIVED A RETROSPTIVE STUDY TO IDENTIFY CLINICAL FACTORS ASSOCIATED WITH SERM TROUGH CONCENTIONS OF VANCOMYCIN CRYSTALLINE DEGRADATION PRODUCT (CDP-1) IN PATINS WITH CHRONIC KIDNEY DISEASE (CKD).
They included Patients with ckd receiving intravenous vancomycin and available steady-state Serum Trough Levels. PAIENTS WERE DIVIDED INTO THREE GROUPS BASED ON ESTIMATED CREATININE CLEARANCE (ECRCL): G1 (60
The Results Showed That Among 167 Patients, 49 (29.34%) Were in G1, 69 (41.32%) in G2, and 49 (29.34%) in G3. Significant Differences in CDP-1 Trough Concentrations and VCia/VUPLC-MS/MS Ratos Were Found Between The Groups. Multivariate Analysis Showed That ECRCL Levels (P<0.001), Time from the Initial Dose to the Trough Level (P<0.001), and vancomycin dose (P<0.001) Were Associated with CDP-1 Trough Concentrations. The CDP-1 Trough Concentration was positively associated with the VCia/VUPLC-MS/MS Ratio (P= 0.002).
Investigators Found that delayed Trough Level Sampling Could Increase CDP-1 Levels and Overestimate Vancomycin Levels, Particularly in Patients with Severe Renal Dysfunction. Then Suggested Increasing TDM Frequency and Using Quantitative Methods to Measter Vancomycin Without Interference from CDP-1.
Source: bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04101-7
